Answer
Allergen-specific IgG4 induced by Itulazax competes with IgE for allergen binding, thereby reducing immune cell activation, although the exact mechanism underlying clinical efficacy is not fully understood.
Sources for this answer
- ITULAZAX 12 SQ-BetALK-Abello Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 7Document updated
Sources checked